Fig. 1
FOXO3 signaling is activated in hepatocellular carcinoma patients, and hepatocyte-specific activation of FOXO3 causes extensive hepatocyte damage. a Detection of activated FOXO3 in livers of patients in HCC or non-HCC groups (left and middle panels) and magnification (right panel) as determined by FOXO3 immunohistochemistry (bar = 100 μm). b Quantification of FOXO3-positive cells as a percentage of total hepatocytes/cancer cells in livers of patients in HCC (n = 27) or non-HCC groups (n = 6). c Expression of FOXO3 by qPCR in livers of patients in HCC or in non-HCC groups (n = 11). d Western blot analysis in livers from 9-week-old control and FOXO3CAHep mice with FOXO3 and GAPDH as loading control (upper panel), as well as densitometric quantification (lower panel). e Representative hematoxylin and eosin and IHC staining for FOXO3 (bar = 100 μm). f Body weight and liver weight of 9-week-old control and FOXO3CAHep transgenic mice (n = 4). g Blood glucose levels were measured from control and FOXO3CAHep transgenic mice. h Alanine amino transferase and aspartate amino transferase levels were elevated in 9-week-old FOXO3CAHep versus control mice